You are here: Home: BCU 6|2001: Editor's office

Editor
Neil Love, MD

Associate Editors
Michelle Finkelstein, MD
Richard Kaderman, PhD

Writers
Jennifer Motley, MD
Sally Bogert, RNC, WHCNP

Print Design
John Westmark

Web Design
John Ribeiro

Copy Editor
Pat Morrissey/Havlin

Audio Production
Frank Cesarano

Technical Services
Arly Ledezma

Production Coordinator
Cheryl Dominguez

Editorial Assistant
Patricia McWhorter

Contact Information
Neil Love, MD
Director, Physician and Community Education
University of Miami Conference Center
400 SE Second Avenue, Suite 401
Miami, Florida 33131-2117

Fax: (305) 377-9998
Email: nlove@med.miami.edu

Pharmaceutical agents discussed in this program
Generic Trade Manufacturer
anastrozole Arimidex ® AstraZeneca Pharmaceuticals, LP
capecitabine Xeloda ® Roche
docetaxel Taxotere ® Aventis Pharmaceuticals
doxorubicin hydrochloride Adriamycin ® Pharmacia Corporation
exemestane phosphate Aromasin ® Pharmacia Corporation
gemcit abine HCL Gemzar ® Eli Lilly & Co.
letrozole Femara ® Novartis Pharmaceuticals
leuprolide acetate Lupron ® TAP Pharmaceuticals, Inc.
megestrol acetate Megace ® Bristol-Myers Squibb Company
paclitaxel Taxol ® Bristol-Myers Squibb Company
tamoxifen citrate Nolvadex ® AstraZeneca Pharmaceuticals, LP
toremifene citrate Fareston ® Shire Laboratories, Inc.
trastuzumab Herceptin ® Genentech, Inc.
vinorelbine tartrate Navelbine ® Glaxo Wellcome, Inc.

© NL Communications, Inc. 2001. All rights reserved. This program was supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP. The audio tapes, compact discs, Internet content and accompanying printed material is protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or utilizing any information storage and retrieval system, without written permission from the copyright owner. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. As part of this program, materials and presentations may include information regarding the use of drugs that may be inconsistent with or outside the approved labeling of these products. Healthcare professionals should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. Please refer to the U.S. product information for complete information about each drug.

 

Table of Contents Top of Page

 

Home · Search

Home · Contact us
Terms of use and general disclaimer